Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 27, 2008

View Archived Issues

FTY-720 associated with viral clearance in models of infection

TRPM8 antagonism may attenuate hypersensitivity to cold

NP-12 reduces tau and beta-amyloid pathology in mice

Recent patents report novel treatment options for endocrine disorders

Novel Rac1/Rac1b inhibitors prevent Abeta production, display improved metabolic stability

Animal model of siRNA therapy for HIV infection created

FG-4497 shows promise in rat kidney transplant model

EP-1013 enhances effects of costimulation blockade for islet transplantation

Pfizer unveils potent and selective c-Met inhibitor PF-4254644

New analgesic agents disclosed in recent patent literature

Recent Roche patent describes new treatments for depression, anxiety

Otsuka acquires Interpharma Praha from Interpharma West

AVEO initiates phase Ib combination trial of AV-951 and FOLFOX-6

Avexa and Shire renegotiate apricitabine license agreement

Biofrontera and DSE form license agreement for U.S. Relieva distribution

Galapagos acquires Sareum Holdings' structure-based drug discovery services

Genzyme and Medicines for Malaria Venture collaborate with Advinus

Novosom acquires exclusive license for Isis' CD40-targeted antisense inhibitors

Phase II IMC-A12 and IMC-1121B trial enrolls advanced prostate cancer patients

Zostavax approved in Canada for the prevention of shingles

Ark commences patient enrollment in phase III Vitor pilot study in cachexia

Curis doses first patient in phase I CUDC-101 trial

FDA fast tracks droxidopa for symptomatic neurogenic orthostatic hypotension

FDA grants Glivec priority review for gastrointestinal stromal tumors

FDA issues complete response letter for paliperidone palmitate for schizophrenia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...